TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26653067

Group type: EXPERIMENTAL
Intervention: mHealth intervention with monthly motivational counselling calls and weekly personalised text messages for 12 months
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: mHealth intervention (participants receiving more than 75% of calls)
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: mHealth intervention
Number of subjects: 637

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 637
Study: 24566244

Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.5 to 3.5 vol%) and Remifentanil (0 to 12 ng/ml)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pre-stimulation measures
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Post-stimulation measures
Number of subjects: 40
Study: 23135014

Group type: EXPERIMENTAL
Intervention: Icon(R)Life LLIN
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no net and untreated net)
Number of subjects: 0
Study: 20121764

Group type: EXPERIMENTAL
Intervention: Extra-fine beclomethasone/formoterol (BDP/F) 400/24 microg daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fluticasone propionate/salmeterol (FP/S) 500/100 microg daily
Number of subjects: 30
Study: 18382802

Group type: EXPERIMENTAL
Intervention: Intracoronary shunts
Number of subjects: 100

Group type: COMPARATOR
Intervention: Shuntless operations (Control)
Number of subjects: 100
Study: 15985318

Group type: EXPERIMENTAL
Intervention: ND 5.5 device
Number of subjects: 0

Group type: COMPARATOR
Intervention: XR-1 device
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ND 5.5 device with 2 administrations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ND 5.5 and XR-1 devices
Number of subjects: 0
Study: 11950378

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg once daily
Number of subjects: 0
Study: 10520055

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (200 microg, twice daily)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 46
Study: 7741338

Group type: EXPERIMENTAL
Intervention: Infant/child CPR training (4-hour program)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (no CPR training)
Number of subjects: 83
Study: 1675050

Group type: EXPERIMENTAL
Intervention: Flurbiprofen sodium 0.03% (topically administered to one eye)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (topically administered to the contralateral eye)
Number of subjects: 20
Study: 7023522

Group type: EXPERIMENTAL
Intervention: Captopril (12 patients)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCT) (8 patients)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Captopril + HCT
Number of subjects: 20

Group type: COMPARATOR
Intervention: HCT + Captopril
Number of subjects: 20
Study: 30876469

Group type: EXPERIMENTAL
Intervention: Modified GLB™ program + personalized, genetic-based lifestyle advice for weight management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard GLB™ program + population-based lifestyle advice for weight management
Number of subjects: 0
Study: 29935595

Group type: EXPERIMENTAL
Intervention: Combined therapy (acustimulation/dexamethasone)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Acustimulation
Number of subjects: 454

Group type: COMPARATOR
Intervention: Sham acustimulation/dexamethasone
Number of subjects: 454

Group type: COMPARATOR
Intervention: Sham acustimulation/vehicle
Number of subjects: 454

Group type: COMPARATOR
Intervention: Acustimulation/vehicle
Number of subjects: 454
Study: 26679243

Group type: EXPERIMENTAL
Intervention: Delafloxacin (300 mg, intravenously, twice daily for 5-14 days)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Vancomycin (15 mg/kg, intravenously, twice daily for 5-14 days)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Linezolid (600 mg, intravenously, twice daily for 5-14 days)
Number of subjects: 256
Study: 24563440

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Normobaric oxygen therapy (NBOT)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Troponin-I and CK-MB levels increase
Number of subjects: 201
Study: 23098629

Group type: EXPERIMENTAL
Intervention: Pendular marking device
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Slitlamp marking device
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bubble marking device
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tonometer marking device
Number of subjects: 60
Study: 20619512

Group type: EXPERIMENTAL
Intervention: Multimodal optimization of perioperative care
Number of subjects: 0
Study: 17593070

Group type: EXPERIMENTAL
Intervention: Pantoprazole granules (40 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pantoprazole tablets (40 mg)
Number of subjects: 60
Study: 14976607

Group type: EXPERIMENTAL
Intervention: Praziquantel and mebendazole (treatment every 3 months)
Number of subjects: 317

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 317
Study: 11823735

Group type: EXPERIMENTAL
Intervention: Midnight removal of urinary catheters
Number of subjects: 160

Group type: COMPARATOR
Intervention: 0600 hours removal of urinary catheters
Number of subjects: 160
Study: 10404023

Group type: EXPERIMENTAL
Intervention: 5 g of lactulose
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 g of lactulose
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reference substance
Number of subjects: 12
Study: 7751080

Group type: EXPERIMENTAL
Intervention: Normobaric conditions (VO2maxnorm)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxia (VO2maxhyp)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Normobaric conditions (VO2LTnorm)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxia (VO2LThyp)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hypobaric hypoxia
Number of subjects: 12
Study: 2175022

Group type: EXPERIMENTAL
Intervention: New mixture of internal ester gangliosides
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional multi-vitamin treatment
Number of subjects: 0
Study: 530565

Group type: EXPERIMENTAL
Intervention: Argon laser photocoagulation
Number of subjects: 39

Group type: COMPARATOR
Intervention: Untreated fellow eye
Number of subjects: 39
Study: 30857489

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 168
Study: 30994259

Group type: EXPERIMENTAL
Intervention: Standard rehabilitation (SR) plus water rehabilitation (WR)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Standard rehabilitation (SR)
Number of subjects: 184
Study: 28176290

Group type: EXPERIMENTAL
Intervention: Prompted to explain each observation
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control condition (reporting the observation)
Number of subjects: 3
Study: 25934044

Group type: EXPERIMENTAL
Intervention: PCT-pyuria-based algorithm
Number of subjects: 125

Group type: COMPARATOR
Intervention: Current guidelines (control group)
Number of subjects: 125
Study: 24224521

Group type: EXPERIMENTAL
Intervention: Single bolus of tenecteplase
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 21317197

Group type: EXPERIMENTAL
Intervention: Pilot program addressing childhood obesity with behavioral modification
Number of subjects: 68

Group type: COMPARATOR
Intervention: Matched control group
Number of subjects: 68
Study: 19477404

Group type: EXPERIMENTAL
Intervention: alpha(2C) Del322-325 polymorphism
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: beta(1) Arg389Gly polymorphism
Number of subjects: 526
Study: 17416851

Group type: EXPERIMENTAL
Intervention: Two CT scans at 3 and 12 months
Number of subjects: 414

Group type: COMPARATOR
Intervention: Five CT scans at 3, 6, 9, 12, and 24 months
Number of subjects: 414
Study: 15058698

Group type: EXPERIMENTAL
Intervention: +1.00 add power
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: +1.50 add power
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: +2.00 add power
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: +2.50 add power
Number of subjects: 20
Study: 15879864

Group type: EXPERIMENTAL
Intervention: Oxybutynin plus behavior modification
Number of subjects: 25

Group type: COMPARATOR
Intervention: Behavior modification alone
Number of subjects: 25
Study: 10359410

Group type: EXPERIMENTAL
Intervention: Once-weekly isoniazid (900 mg) and rifapentine (600 mg)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Twice-weekly isoniazid (900 mg) and rifampin (600 mg)
Number of subjects: 71
Study: 8961309

Group type: EXPERIMENTAL
Intervention: Practice of throwing skill from one position (sitting on a Balans chair)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Practice of throwing skill from one position (reclined on a slanted table)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No practice (control group)
Number of subjects: 40
Study: 1850691

Group type: EXPERIMENTAL
Intervention: Beet fiber supplementation (16 g added to ordinary diet)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Beet fiber supplementation
Number of subjects: 13
Study: 6121836

Group type: EXPERIMENTAL
Intervention: Bromazepam (6 mg daily: 1.5 mg at 7 a.m., 1.5 mg at 3 p.m., 3 mg at 11 p.m.)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (same dosage pattern as bromazepam)
Number of subjects: 33
Study: 30930141

Group type: EXPERIMENTAL
Intervention: Erector Spinae Block (ESB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Serratus Plane Block (SPB)
Number of subjects: 60
Study: 28778254

Group type: EXPERIMENTAL
Intervention: 5% dextrose (D5W)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 49
Study: 25906786

Group type: EXPERIMENTAL
Intervention: Normal Glucose Tolerance (NGT)
Number of subjects: 1376

Group type: EXPERIMENTAL
Intervention: Prediabetes
Number of subjects: 1376

Group type: EXPERIMENTAL
Intervention: Any dysglycemia
Number of subjects: 1376

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 1376
Study: 23054802

Group type: EXPERIMENTAL
Intervention: CR-I (60:40 roughage-to-concentrate ratio)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CR-II (50:50 roughage-to-concentrate ratio)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CR-III (40:60 roughage-to-concentrate ratio)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CR-IV (30:70 roughage-to-concentrate ratio)
Number of subjects: 24

Group type: COMPARATOR
Intervention: CR-IV and CR-III
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All diets
Number of subjects: 24
Study: 22219537

Group type: EXPERIMENTAL
Intervention: Game activity for studying course material
Number of subjects: 2

Group type: COMPARATOR
Intervention: No-game condition
Number of subjects: 2
Study: 19725291

Group type: COMPARATOR
Intervention: Southern states patients
Number of subjects: 2025

Group type: COMPARATOR
Intervention: Northern states patients
Number of subjects: 2025
Study: 17694232

Group type: EXPERIMENTAL
Intervention: Multimedia CD (MCD) presented by Registered Nurse (RN) in Group A (n = 15)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Leaflet information in Group B (n = 15)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Verbal information from RN in Group C (n = 15)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional information by attending surgeon and anesthesiologist in Control Group D (n = 15)
Number of subjects: 60
Study: 15155303

Group type: EXPERIMENTAL
Intervention: IA saline 10 mL
Number of subjects: 60

Group type: COMPARATOR
Intervention: IA saline 1 mL (placebo)
Number of subjects: 60
Study: 11463597

Group type: EXPERIMENTAL
Intervention: Formoterol Turbohaler 9 microg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Salbutamol 200 microg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9886506

Group type: EXPERIMENTAL
Intervention: 0.5 mg leuprolide acetate (GnRHa) for ovulation induction
Number of subjects: 26

Group type: COMPARATOR
Intervention: Human chorionic gonadotrophin (HCG) 10,000 IU i.m. for ovulation induction
Number of subjects: 26
Study: 8294618

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg q.d.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg b.i.d.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 30289327

Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic surgery (RALS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Laparotomy (LT)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: EuroQol Eq5D
Number of subjects: 120
Study: 27307362

Group type: EXPERIMENTAL
Intervention: Mini-Midvastus (MMV) approach
Number of subjects: 97

Group type: COMPARATOR
Intervention: Conventional total knee arthroplasty
Number of subjects: 97
Study: 25638572

Group type: EXPERIMENTAL
Intervention: Desflurane anesthesia (3.5%)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sevoflurane anesthesia (1.0%)
Number of subjects: 42
Study: 23622917

Group type: EXPERIMENTAL
Intervention: Intra-arterial contrast injection
Number of subjects: 170

Group type: COMPARATOR
Intervention: Intravenous contrast administration
Number of subjects: 170
Study: 20639734

Group type: EXPERIMENTAL
Intervention: Naprapathic manual therapy
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conventional orthopedic care
Number of subjects: 78
Study: 18469237

Group type: EXPERIMENTAL
Intervention: C12 (lauric acid)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: C18 (oleic acid)
Number of subjects: 13

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 13
Study: 16968504

Group type: EXPERIMENTAL
Intervention: IV pantoprazole (PAN) 80 mg plus 8 mg/h for 72 h
Number of subjects: 149

Group type: COMPARATOR
Intervention: IV ranitidine (RAN) 50 mg plus 6.25 mg/h for 72 h
Number of subjects: 149
Study: 14586600

Group type: EXPERIMENTAL
Intervention: Dolasetron mesilate
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 11107929

Group type: EXPERIMENTAL
Intervention: Nicotinamide
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 9108644

Group type: EXPERIMENTAL
Intervention: Trihexyphenidyl (8 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Biperiden (6 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 20
Study: 8099803

Group type: EXPERIMENTAL
Intervention: Atenolol, 100 mg once daily
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Metoprolol, 50 mg three times daily
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Propranolol, single 40 mg dose
Number of subjects: 34
Study: 2869703

Group type: EXPERIMENTAL
Intervention: Lactate infusions
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Chronic alprazolam treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo infusions
Number of subjects: 25
Study: 31362262

Group type: EXPERIMENTAL
Intervention: EIMD group received a treatment to induce muscle damage consisting of a weight lifting protocol directed to the agonist muscles related to the task prior to the pretest and to the learning sessions.
Number of subjects: 30

Group type: COMPARATOR
Intervention: CON group (control group) did not receive the EIMD treatment.
Number of subjects: 30
Study: 30218170

Group type: EXPERIMENTAL
Intervention: Home intravenous (IV) ertapenem
Number of subjects: 82

Group type: COMPARATOR
Intervention: Oral amoxicillin‐clavulanate
Number of subjects: 82
Study: 26368863

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active treatment responders
Number of subjects: 0
Study: 25320894

Group type: EXPERIMENTAL
Intervention: Web-based training system for CHAs; 13 training videos, average completion time of 26 days.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Implementation of cancer early detection workshops by trained CHAs.
Number of subjects: 12
Study: 22585642

Group type: EXPERIMENTAL
Intervention: Misoprostol (Cytotec ®)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Dinoprostone (Prépidil ®)
Number of subjects: 300
Study: 20187985

Group type: EXPERIMENTAL
Intervention: High total meat consumption
Number of subjects: 24845

Group type: EXPERIMENTAL
Intervention: Processed meat consumption
Number of subjects: 24845

Group type: COMPARATOR
Intervention: Red meat and poultry consumption
Number of subjects: 24845
Study: 18309301

Group type: EXPERIMENTAL
Intervention: Internet intervention (n=66)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Self-directed weight maintenance (n=69)
Number of subjects: 135
Study: 16044981

Group type: EXPERIMENTAL
Intervention: Self-care intervention group
Number of subjects: 2242

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 2242
Study: 11817499

Group type: EXPERIMENTAL
Intervention: HUFA supplementation
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 9922346

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (1.5 x 10^6 U over 30 to 60 minutes)
Number of subjects: 251
Study: 7547516

Group type: EXPERIMENTAL
Intervention: Aggressive management aimed at cure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Expectant medical management ('watchful waiting')
Number of subjects: 0
Study: 2281830

Group type: EXPERIMENTAL
Intervention: Lidocaine plus bicarbonate
Number of subjects: 28

Group type: COMPARATOR
Intervention: Plain lidocaine
Number of subjects: 28
Study: 442224

Group type: EXPERIMENTAL
Intervention: peptichemio at 1.2 mg/kg twice weekly
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: peptichemio at 0.9 mg/kg twice weekly
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: peptichemio at 1.3 mg/kg once weekly combined with other cytostatic drugs
Number of subjects: 32
Study: 31927349

Group type: EXPERIMENTAL
Intervention: Eccentric exercise (EE) program plus vibration for 12 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: Eccentric exercise (EE) program plus cryotherapy for 12 weeks
Number of subjects: 61
Study: 30882563

Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI) at 13 ± 1° C for 15 minutes
Number of subjects: 64

Group type: COMPARATOR
Intervention: Passive recovery for 15 minutes
Number of subjects: 64
Study: 27667324

Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 27265706

Group type: EXPERIMENTAL
Intervention: Lifestyle coaching plus care coordination plus treatment as usual (N=138)
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Care coordination plus treatment as usual (N=142)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Treatment as usual alone (N=148)
Number of subjects: 428
Study: 25124733

Group type: EXPERIMENTAL
Intervention: Capsaicin-contained red pepper sauce (acute infusion)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Capsaicin-contained red pepper sauce (repeated infusion)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 15
Study: 21921823

Group type: EXPERIMENTAL
Intervention: 2‐nitrooxy ethyl 2‐amino 3‐methylbutanoate gel
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (tea tree oil)
Number of subjects: 14
Study: 19152118

Group type: EXPERIMENTAL
Intervention: Dynamically Modified Outcomes (DYNAMO)
Number of subjects: 0
Study: 17472154

Group type: EXPERIMENTAL
Intervention: Warmed intravenous fluids using a dry IV fluid warmer (normothermia group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Room temperature intravenous fluids (hypothermia group)
Number of subjects: 60
Study: 16388166

Group type: EXPERIMENTAL
Intervention: McCoy laryngoscope and fentanyl
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: McCoy laryngoscope and no fentanyl
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope and fentanyl
Number of subjects: 180

Group type: COMPARATOR
Intervention: Macintosh laryngoscope and no fentanyl
Number of subjects: 180
Study: 11991773

Group type: EXPERIMENTAL
Intervention: Exercise physiology program (theory + active aerobic and resistance exercise)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Standard biology course (control group)
Number of subjects: 161
Study: 9861410

Group type: EXPERIMENTAL
Intervention: Loading dose of quinine (20 mg/kg)
Number of subjects: 113

Group type: COMPARATOR
Intervention: No loading dose of quinine
Number of subjects: 113
Study: 8556417

Group type: EXPERIMENTAL
Intervention: ASMT 1 (1 hour a week)
Number of subjects: 22000

Group type: EXPERIMENTAL
Intervention: ASMT 2 (3 hours a week)
Number of subjects: 22000

Group type: EXPERIMENTAL
Intervention: ASMT 3 (competitors)
Number of subjects: 22000

Group type: COMPARATOR
Intervention: Sedentary group
Number of subjects: 22000
Study: 2370391

Group type: EXPERIMENTAL
Intervention: Shrimp challenges (double-blind, placebo-controlled)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Shrimp hypersensitivity
Number of subjects: 21

Group type: COMPARATOR
Intervention: Shrimp ingestion
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Shrimp challenges
Number of subjects: 21
Study: 7010536

Group type: EXPERIMENTAL
Intervention: Cefamandole prophylaxis
Number of subjects: 140

Group type: COMPARATOR
Intervention: Penicillin/Flucloxacillin prophylaxis
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 140
Study: 31584516

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 2549

Group type: EXPERIMENTAL
Intervention: Lower SBP-CoV tertile
Number of subjects: 2549

Group type: EXPERIMENTAL
Intervention: Higher SBP-CoV
Number of subjects: 2549

Group type: EXPERIMENTAL
Intervention: Lower SBP-CoV
Number of subjects: 2549

Group type: EXPERIMENTAL
Intervention: Mean SBP and SBP-CoV interaction
Number of subjects: 2549
Study: 28643119

Group type: EXPERIMENTAL
Intervention: Home-based aerobic exercise
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Center-based aerobic exercise
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 40
Study: 26626993

Group type: EXPERIMENTAL
Intervention: lenalidomide
Number of subjects: 94

Group type: COMPARATOR
Intervention: lenalidomide plus epoetin β
Number of subjects: 94
Study: 25574674

Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg + 2800 IU cholecalciferol once per week
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo + 2800 IU cholecalciferol once per week
Number of subjects: 40
Study: 22716474

Group type: EXPERIMENTAL
Intervention: NRXN3 SNPs (specifically rs221473 and rs221497)
Number of subjects: 157

Group type: COMPARATOR
Intervention: NRXN3 CNV
Number of subjects: 157